Long-term outcome of drug prescription in 174 patients with myocardial infarction followed up for 4.5 years (DEVENIR study);EVOLUTION A LONG TERME DE LA PRESCRIPTION MEDICAMENTEUSE CHEZ 174 PATIENTS ATTEINTS D'INFARCTUS DU MYOCARDE SUIVIS PENDANT 4,5 ANS (ETUDE DEVENIR)

Archives des Maladies du Coeur et des Vaisseaux

Volumn 89, Issue 1, 1996, Pages 35-39

  Graille, V ^a   Ferrieres J ^a   Marques Vidal, P ^a   Ruidavets, J B ^a   Rodier, P ^a   Cambou, J P ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; MOLSIDOMINE; NITRATE; CARDIOVASCULAR AGENT;

ARTICLE; CORONARY ARTERY DISEASE; GOOD CLINICAL PRACTICE; HEART INFARCTION; HOSPITALIZATION; HUMAN; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; ADULT; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; DRUG COMBINATION; DRUG UTILIZATION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL;

ADULT; CARDIOVASCULAR AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 0030067264     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. AHA Medical/Scientific Statement. ACC/AHA Guidelines for the early management of patients with myocardial infarction. Circulation 1990 ; 82 : 604-707.
2. ISIS-2 (Second International Study of lnfarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction : ISIS-2. Lancet 1988 ; ii : 349-60.
3. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA 1992 ; 268 : 240-8
4. Gruppo ltaliano per lo Studio della Streptochinnsi aell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986 ; i : 397-402.
5. Wilcox RS, Von Der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction : Anglo-Scandinavian Study of Early Thrombolysin (ASSET). Lancet 1988 ; ii : 525-30.
6. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction : preliminary report of a placebo-controlled clinical trial Lancet 1988 ; ii . 545-9.
7. Gruppo ltaliano per lo Studio della Streptochinnsi aell'Infarto Miocardico GISSI-2 : a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction Lancet 1990 ; 336 : 65-71.
8. Third International Study of lnfarct Survival Collaborative Group ISIS-3. ISIS-3 : a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 298 cases of suspected acute myocardial infarction. Lancet 1992 ; 339 . 753-70.
9. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction : an overview of the randomized trials. Prog Cardiovasc Dis 1985 ; 17 : 335-71.
10. ISIS-1 Collaborative Group. Randomized trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction . ISIS-1 Lancet 1986 ; ii : 57-66.
11. Rogers WJ, Bowlby LJ, Chandra NC et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994 , 90 2103-14.
12. Ferrières J, Cambou JP, Ruidavets JB, Douste-Blazy P, Richard JL Comparaison du pronostic et du traitement de l'infarctus du myocarde en Haute-Garonne entre 1986 et 1989, Arch Mal Cœur 1992 ; 85 : 1463-9.
13. Béard T, Carrié D, Pachins B, Jaillais P, Delay M, Bernadet P. Suivi àun un de 328 patients atteints d'infarctus du myocarde. Arch Mal Cœur 1994 ; 87; 869-73.
14. Brandt CM, Wees-Ponchon A, Nisand G et al. Survie dans l'infarctus du myocarde au stade aigu dans un groupe de 369 patients admis consécutivement entre 1988 et 1992. Arch Mal Cœur 1994 ; 87 : 861-8.
15. Lamas GA, Pfeffer MA, Hamm P et al. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice ? N Engl J Med 1992 ; 327 : 241-7.
16. Richard JL. Le projet MONICA. Un projet OMS de recherche cardiovasculaire. Rev Epidemiol Sante Publ 1988 , 36 : 325-34.
17. WHO MONICA Project, prepared by Tunstall-Pedoe H. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease) : a major international collaboration. J Clin Epidemiol 1988 ; 41 : 105-13
18. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D., Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Circulation 1994 ; 90 : 583-612.
19. Parra HJ, Arveiler D, Evans AE et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM study. Arterioscler Thromb 1992; 12 : 701-7.
20. Schlesselman JJ. Case-control studies New York : Oxford University Press 1982 : 203-6.
21. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined Colestipol-Niacin Therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987 ; 257 : 3233-40
22. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 1990 ; 323: 1289-98.
23. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, McGovern ME for the PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) (abstract). J Am Coll Cardiol 1994; 23 (suppl A) : A 131.
24. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease : the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 ; 344 : 1383-9.
25. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 ; 325 : 293-302.
26. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 1992 ; 327 : 685-91
27. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction : results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992; 327: 669-77.
28. Rees Willet L, Carson JL, Strom BL. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Saf 1994 ; 10 170-81.
29. Gibson RS, Boden WE, Theroux P et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction : results of a double-blind, randomized, multicenter trial. N Engl J Med 1986 ; 315 : 423-9.
30. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction : the Danish Verapamil Infarction Trial II (DAVIT II). Am J Cardiol 1990 ; 66 : 779-85.
31. The Cardiac Arrhythmias Suppression Trial (CAST) Investigators. Preliminary report : effect of encainide or flecainide on mortality in a randomized trial of arrythmia suppression after myocardial infarction. N Engl J Med 1989 ; 321 : 406-12.